# A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

> **NCT00448136** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 83 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** 5 FU
- **DRUG:** Streptozotocin
- **DRUG:** Xeloda

## Key facts

- **NCT ID:** NCT00448136
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2015-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448136, "A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00448136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*